Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tony Lu

Vascular Surgery Sugar Land, TX Medical Doctor

NPI 1265876338 CMS profile 102980

16605 Southwest Fwy Ste 560, Sugar Land, TX 77479

Open in the dashboard

General payments

$14,382

323 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tony Lu of Sugar Land, TX is reported in the CMS Open Payments database as having received $14,382 across 323 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,880 80
2024 General $1,909 44
2023 General $1,335 36
2022 General $3,405 60
2021 General $2,304 70
2020 General $571 17
2019 General $977 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tony Lu
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Tony Lu were reported at $3,880. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Tony Lu Vascular Surgery median Middle half National median
2019 $977 $796 $226–$2,363 $163
2020 $571 $348 $118–$1,110 $114
2021 $2,304 $471 $158–$1,421 $132
2022 $3,405 $725 $222–$2,183 $149
2023 $1,335 $836 $257–$2,440 $160
2024 $1,909 $909 $252–$2,619 $164
2025 $3,880 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,644 29 payments
  2. Endologix, Inc. $1,622 13 payments
  3. Penumbra, Inc. $1,397 6 payments
  4. Cook Medical LLC $1,065 24 payments
  5. Bolton Medical Inc $940 21 payments
  6. Janssen Pharmaceuticals, Inc $852 43 payments
  7. Stryker Corporation $759 13 payments
  8. Silk Road Medical, Inc. $750 9 payments
  9. Medtronic, Inc. $589 11 payments
  10. Inari Medical, Inc. $533 22 payments
  11. Other $4,231 132 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,891 319 payments
  2. Consulting Fee $781 1 payment
  3. Travel and Lodging $687 2 payments
  4. Entertainment $22 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $1,239 4 payments
  2. AngioJet Ultra 5000A $895 4 payments
  3. XARELTO $852 43 payments
  4. ENROUTE Transcarotid Stent $600 8 payments
  5. ENROUTE Transcarotid Neuroprotection System $600 8 payments
  6. CT THROMBECTOMY SYSTEM KIT $584 24 payments
  7. FLOWTRIEVER CATHETER, S $584 24 payments
  8. Zilver PTX $533 11 payments
  9. FLOWTRIEVER $512 3 payments
  10. Grafts $458 7 payments
  11. Other $9,758 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

324

Median for Vascular Surgery: 122

Drug cost

$94,395

Median for Vascular Surgery: $14,135

Branded share of claims

77.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 62 $54,558
Eliquis Apixaban Brand 62 $37,949
Clopidogrel Clopidogrel Bisulfate Brand 116 $1,189
Cilostazol Generic 15 $245
Atorvastatin Calcium Generic 23 $188
Clindamycin Hcl Generic 15 $115
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $99
Tramadol Hcl Generic 19 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 122 billing codes

Paid by Medicare

$209,053

Medicare's payments for the services billed

Medicare patients

605

Average age 75

Services billed

2,334

306 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 59%
Chronic kidney disease 57%
Diabetes 55%
Heart failure 45%
Atrial fibrillation 30%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $122
$122 62 —
FIBRYGA
  • Octapharma USA, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record